Genome-wide analysis of the homeobox C6 transcriptional network in prostate cancer

Cancer Research

Volumn 68, Issue 6, 2008, Pages 1988-1996

  McCabe, Colleen D ^a   Spyropoulos, Demetri D ^b   Martin, David ^a   Moreno, Carlos S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 2; HOMEOBOX C6; HOMEODOMAIN PROTEIN; NOTCH RECEPTOR; OSTEOGENIC PROTEIN 1; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; SOMATOMEDIN BINDING PROTEIN 3; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; ARTICLE; BONE METASTASIS; CANCER CELL; CANCER INHIBITION; CARCINOGENICITY; CELL PROLIFERATION; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; MALE; MORPHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BONE MORPHOGENETIC PROTEINS; CARD SIGNALING ADAPTOR PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CORE BINDING FACTOR ALPHA 2 SUBUNIT; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, HUMAN; HOMEODOMAIN PROTEINS; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; MALE; MICE; MICE, KNOCKOUT; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA;

EID: 40949128823     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-5843     Document Type: Article

References (47)

1. Veraksa A, Del Campo M, McGinnis W. Developmental patterning genes and their conserved functions: from model organisms to humans. Mol Genet Metab 2000;69:85-100.
2. Abate-Shen C. Deregulated homeobox gene expression in cancer: cause or consequence? Nat Rev Cancer 2002;2:777-85.
3. Miller GJ, Miller HL, van Bokhoven A, et al. Aberrant HOXC expression accompanies the malignant phenotype in human prostate. Cancer Res 2003;63:5879-88.
4. Bibikova M, Chudin E, Arsanjani A, et al. Expression signatures that correlated with Gleason score and relapse in prostate cancer. Genomics 2007;89:666-72.
5. Ramachandran S, Liu P, Young AN, et al. Loss of HOXC6 expression induces apoptosis in prostate cancer cells. Oncogene 2005;24:188-98.
6. Zhao Y, Potter SS. Functional comparison of the Hoxa 4, Hoxa 10, and Hoxa 11 homeoboxes. Dev Biol 2002;244:21-36.
7. Odom DT, Zizlsperger N, Gordon DB, et al. Control of pancreas and liver gene expression by HNF transcription factors. Science 2004;303:1378-81.
8. Ren B, Robert F, Wyrick JJ, et al. Genome-wide location and function of DNA binding proteins. Science 2000;290:2306-9.
9. Buck MJ, Nobel AB, Lieb JD. ChIPOTle: a user-friendly tool for the analysis of ChIP-chip data. Genome Biol 2005;6:R97.
10. Garcia-Gasca A, Spyropoulos DD. Differential mammary morphogenesis along the anteroposterior axis in Hoxc6 gene targeted mice. Dev Dyn 2000;219:261-76.
11. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
12. Macisaac KD, Gordon DB, Nekludova L, et al. A hypothesis-based approach for identifying the binding specificity of regulatory proteins from chromatin immunoprecipitation data. Bioinformatics 2006;22:423-9.
13. Karanam S, Moreno CS. CONFAC: automated application of comparative genomic promoter analysis to DNA microarray data sets. Nucleic Acids Res 2004;32:W475-84.
14. Shang Z, Ebright YW, Iler N, et al. DNA affinity cleaving analysis of homeodomain-DNA interaction: identification of homeodomain consensus sites in genomic DNA. Proc Natl Acad Sci U S A 1994;91:118-22.
15. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004;6:1-6.
16. Liu P, Ramachandran S, Ali-Seyed M, et al. Sex-determining region Y box 4 is a transforming oncogene in human prostate cancer cells. Cancer Res 2006;46:4011-9.
17. Matei D, Chang DD, Jeng MH. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor α and Akt inactivation. Clin Cancer Res 2004;10:681-90.
18. Lin Y, Liu G, Zhang Y, et al. Fibroblast growth factor receptor 2 tyrosine kinase is required for prostatic morphogenesis and the acquisition of strict androgen dependency for adult tissue homeostasis. Development 2007;134:723-34.
19. Gakunga P, Frost G, Shuster S, Cunha G, Formby B, Stern R. Hyaluronan is a prerequisite for ductal branching morphogenesis. Development 1997;124:3987-97.
20. Grishina IB, Kim SY, Ferrara C, Makarenkova HP, Walden PD. BMP7 inhibits branching morphogenesis in the prostate gland and interferes with Notch signaling. Dev Biol 2005;288:334-47.
21. Ricort JM, Binoux M. Insulin-like growth factorbinding protein-3 activates a phosphotyrosine phosphatase. Effects on the insulin-like growth factor signaling pathway. J Biol Chem 2002;277:19448-54.
22. van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994;10:251-337.
23. Strom DK, Nip J, Westendorf JJ, et al. Expression of the AML-1 oncogene shortens the G(1) phase of the cell cycle. J Biol Chem 2000;275:3438-45.
24. Matsubara A, Kan M, Feng S, McKeehan WL. Inhibition of growth of malignant rat prostate tumor cells by restoration of fibroblast growth factor receptor 2. Cancer Res 1998;58:1509-14.
25. Naimi B, Latil A, Fournier G, Mangin P, Cussenot O, Berthon P. Down-regulation of (IIIb) and (IIIc) isoforms of fibroblast growth factor receptor 2 (FGFR2) is associated with malignant progression in human prostate. Prostate 2002;52:245-52.
26. Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H. Functional epigenomics identifies genes frequently silenced in prostate cancer. Cancer Res 2005;65:4218-27.
27. Wissmann C, Wild PJ, Kaiser S, et al. WIF1, a component of the Wnt pathway, is down-regulated in prostate, breast, lung, and bladder cancer. J Pathol 2003;201:204-12.
28. Park S, Kim JH, Jang JH. Aberrant hypermethylation of the FGFR2 gene in human gastric cancer cell lines. Biochem Biophys Res Commun 2007;357:1011-5.
29. Zhu X, Lee K, Asa SL, Ezzat S. Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol 2007;170:1618-28.
30. Lou W, Krill D, Dhir R, et al. Methylation of the CD44 metastasis suppressor gene in human prostate cancer. Cancer Res 1999;59:2329-31.
31. Zou H, Molina JR, Harrington JJ, et al. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus. Int J Cancer 2005;116:584-91.
32. Franceschi RT, Wang D, Krebsbach PH, Rutherford RB. Gene therapy for bone formation: in vitro and in vivo osteogenic activity of an adenovirus expressing BMP7. J Cell Biochem 2000;78:476-86.
33. Buijs JT, Rentsch CA, van der Horst G, et al. BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 2007;171:1047-57.
34. Soriano P. The PDGF α receptor is required for neural crest cell development and for normal patterning of the somites. Development 1997;124:2691-700.
35. Sulzbacher I, Birner P, Trieb K, Traxler M, Lang S, Chott A. Expression of platelet-derived growth factor-AA is associated with tumor progression in osteosarcoma. Mod Pathol 2003;16:66-71.
36. Chott A, Sun Z, Morganstern D, et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor. Am J Pathol 1999;155:1271-9.
37. Dolloff NG, Shulby SS, Nelson AV, et al. Bonemetastatic potential of human prostate cancer cells correlates with Akt/PKB activation by α platelet-derived growth factor receptor. Oncogene 2005;24:6848-54.
38. Draffin JE, McFarlane S, Hill A, Johnston PG, Waugh DJ. CD44 potentiates the adherence of metastatic prostate and breast cancer cells to bone marrow endothelial cells. Cancer Res 2004;64:5702-11.
39. Patrawala L, Calhoun T, Schneider-Broussard R, et al. Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 2006;25:1696-708.
40. Wang XD, Leow CC, Zha J, et al. Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. Dev Biol 2006;290:66-80.
41. Dhanasekaran SM, Barrette TR, Ghosh D, et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822-6.
42. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007;39:41-51.
43. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 2004;101:811-6.
44. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005;8:393-406.
45. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.
46. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-9.
47. Yu YP, Landsittel D, Jing L, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22:2790-9.